NO NO NO NO NO NO NO


[PDF]NO NO NO NO NO NO NO - Rackcdn.comhttps://75c17d9f6eecafb09b78-695e1a25d6559f5c6a6714b54be309d0.ssl.cf3.rackcd...

4 downloads 344 Views 46KB Size

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2015 OS PC DESPATCHED ON 24TH MARCH 2015 HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B8, B35; Cw4, Cw7; DR1, DR17; DQ2, DQ5 Summary of Results PBL/T-Cells

B-Cells

Total tested Positive Negative NT/Equivocal % Positive % Negative

29 13 16 3 44.8% 55.2%

30 1 29 3 3.3% 96.7%

29 3 26 4 10.3% 89.7%

30 5 25 3 16.7% 83.3%

23 23 0 1 100.0% 0.0%

23 0 23 1 0.0% 100.0%

23 4 19 1 17.4% 82.6%

22 5 17 2 22.7% 77.3%

Consensus

Not Assessed

Negative

Negative

Negative

Positive

Negative

Negative

Negative

DQ1

DQ3

A2, B17

A9, DR15

DQ1

DQ3

A2, B17

A9, DR15

Serum 1

Without DTT Serum 2 Serum 3

Serum 4

Serum 1

Without DTT Serum 2 Serum 3

Serum 4

Positive Positive Negative Positive Negative Negative Negative Negative Negative Negative NT Positive Positive Negative Negative Negative NT NT Negative Positive Negative Positive Positive Negative Positive Positive Positive Negative Positive Positive Negative Negative

Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative

Negative Positive Positive Negative Negative Negative Negative Negative Negative Negative Negative NT Positive Positive Negative Negative Negative NT NT Negative Negative Negative Negative Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative

Positive

Negative

Negative

Positive

Positive

Negative

Positive

Positive

Positive Positive Positive Positive

Negative Negative Negative Negative

Negative Negative Negative Negative

Equivocal Negative Negative Negative

Positive Positive Positive Positive Positive NT Weak Positive Positive

Negative Negative Negative Negative Negative NT Negative Negative

Positive Positive Negative Negative Negative NT Negative Negative

Positive Positive Negative Negative Negative NT Negative Negative

Positive

Negative

Negative

Negative

Positive Positive Positive Positive Positive Positive Positive Positive Positive

Negative Negative Negative Negative Negative Negative Negative Negative Negative

Positive Negative Negative Negative Negative Negative Negative Negative Negative

Positive Negative Negative Negative Negative Negative Negative Negative Negative

HLA Antibody Specificity (Defined By CDC)

Lab No. 112 116 119 120 128 139 143 147 154 157 159 174 181 189 190 193 194 195 197 209 216 223 229 232 238 245 252 259 260 262 293 294 297

PBL/T Cell

B Cell

Assessment Assessment

YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES

NO NO

NO YES NO YES

NO YES YES YES YES

NO YES YES YES YES YES YES YES YES

NO YES NO

NO YES YES YES YES YES YES YES YES YES

Negative Negative Equivocal Negative Negative Negative Negative Negative Negative Negative Negative NT Positive Positive Negative Negative Negative NT NT Negative Negative Negative Negative Negative Positive Negative Negative Negative Negative Negative Negative Negative Negative

Poor cell viability

Page 1 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

No results returned Poor T cell viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A04/2015 OS PC DESPATCHED ON 24TH MARCH 2015

Lab No. 112 116 119 120 128 139 143 147 154 157 159 174 181 189 190 193 194 195 197 209 216 223 229 232 238 245 252 259 260 262 293 294 297

Serum 1 reaction strength

PBL/T-cell without DTT Serum 2 Serum 3 reaction reaction strength strength

Serum 4 reaction strength

6 6 6 1 4 1 1 1 1

-1 6 1 1 1 1 1 1 1

-2 1 2 1 1 1 1 1 1

-1 4 4 1 1 1 1 1 1

1 NT 6 6 5% 1 1

1 NT 1 1 5% 1 1

1 NT 4 6 5% 1 1

1 NT 4 6 5% 1 1

NT

NT

NT

NT

Serum 1 reaction strength

B-cell without DTT Serum 2 Serum 3 reaction reaction strength strength

Serum 4 reaction strength

Cell viability % PBL T-cells B-cells 90 90

NT 8

NT 1

NT 1

NT 2

8

1

4

8

8 8

1 1

1 1

2 1

8

1

1

1

8 6 95% 3 8

2 1 10% 1 1

4 6 10% 1 1

4 6 15% 1 1

95 80 80

100

83 92

100 80

8 6 1 90% 6+ 1 6 4-6

4 8+ 0 1

1 1

1 1 1

0 1

2 1

2 1 1-2

0 1

2 1

100

100

80 90 100 95 100 100

80 100 95 100 100

90 95 99 98

83 88 95 99 98

40 95

70 90

90

80

90 100

80 100 50 85 90 100 60 95 80

90 6

4 1 1

8 6 4-6

0 1

+++ 8 8+ 4 8

1

1 1 1

1

4 1 1-2

2

6 1 1

90 80 90 100 60 90 100

0 1

0 1

0 1

80

80 90 100 70 95 80

Page 2 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2015 OS PC DESPATCHED ON 24TH MARCH 2015 HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B8, B35; Cw4, Cw7; DR1, DR17; DQ2, DQ5 Summary of Results PBL/T-Cells

B-Cells

Total tested Positive Negative NT/Equivocal % Positive % Negative

23 11 12 4 47.8% 52.2%

23 0 23 4 0.0% 100.0%

23 2 21 4 8.7% 91.3%

23 5 18 4 21.7% 78.3%

20 20 0 2 100.0% 0.0%

20 0 20 2 0.0% 100.0%

20 3 17 2 15.0% 85.0%

19 5 14 3 26.3% 73.7%

Consensus

Not Assessed

Negative

Negative

Negative

Positive

Negative

Negative

Not Assessed

DQ1

DQ3

A2, B17

A9, DR15

DQ1

DQ3

A2, B17

A9, DR15

Serum 1

With DTT Serum 2 Serum 3

Serum 4

Serum 1

With DTT Serum 2 Serum 3

Serum 4

Positive Positive Positive Negative Negative Negative NT

Negative Negative Negative Negative Negative Negative NT

Negative Negative Negative Negative Negative Negative NT

Negative Positive Positive Negative Negative Negative NT

Negative NT Positive Positive Negative Negative Negative NT NT Negative Positive Positive Negative Positive Positive Negative Positive Positive Negative Negative

Negative NT Negative Negative Negative Negative Negative NT NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative

Negative NT Positive Positive Negative Negative Negative NT NT Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative Negative

Negative NT Positive Positive Negative Negative Negative NT NT Negative Negative Negative Positive Negative Negative Negative Negative Negative Negative Negative

Positive Positive Positive NT Positive Positive

Negative Negative Negative NT Negative Negative

Negative Negative Negative NT Negative Negative

Positive Positive Equivocal NT Negative Negative

Positive Positive Positive Positive Positive NT Weak Positive Positive

Negative Negative Negative Negative Negative NT Negative Negative

Positive Positive Negative Negative Negative NT Negative Negative

Positive Positive Negative Negative Negative NT Negative Negative

Positive Positive Positive Positive Positive Positive Positive Positive

Negative Negative Negative Negative Negative Negative Negative Negative

Positive Negative Negative Negative Negative Negative Negative Negative

Positive Negative Negative Negative Negative Negative Negative Negative

HLA Antibody Specificity (Defined By CDC)

Lab No. 112 116 119 120 139 147 154 157 159 174 181 189 190 193 194 195 197 209 216 229 238 245 252 260 262 293 294 297

PBL/T Cell

B Cell

Assessment

Assessment

YES YES YES YES YES YES YES NO YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES YES

NO NO

NO YES YES YES YES YES YES NO YES YES YES YES YES YES YES YES

NO NO YES YES YES YES YES YES YES YES

Low cell count

Poor cell viability

Page 3 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

No results returned Poor T cell viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A04/2015 OS PC DESPATCHED ON 24TH MARCH 2015

Lab No. 112 116 119 120 139 147 154 157 159 174 181 189 190 193 194 195 197 209 216 229 238 245 252 260 262 293 294 297

Serum 1 reaction strength 6 6 4 1 1 1 NT

PBL/T-cell with DTT Serum 2 Serum 3 reaction reaction strength strength -1 1 1 1 1 1 NT

-2 1 1 1 1 1 NT

Serum 4 reaction strength -1 4 2 1 1 1 NT

Serum 1 reaction strength

B-cell with DTT Serum 2 Serum 3 reaction reaction strength strength

Serum 4 reaction strength

Cell viability % PBL T-cells B-cells 90 90 95

8 8 6 NT

1 1 1 NT

1 1 1 NT

2 6 2 NT

80

100 1 NT 6 6 5% 1 1

1 NT 1 1 5% 1 1

1 NT 4 6 5% 1 1

1 NT 4 6 5% 1 1

NT

NT

NT

NT

6

1

1

1

8 6 90% 4 8

2 1 5% 1 1

4 6 5% 1 1

4 6 5% 1 1

83 92

100 80

4 6 90% 1 6 4-6 4 8+ 0 1

1

2

2

1 1 1

1 1 1

4 1 1

0 1

0 1

0 1

8 6 4-6 +++ 8 8+ 6 8

1 1 1

4 1 1

6 1 1

90 90 90 100 60 100

0 1

0 1

2 1

80

100 80 100 95 100 100

100 80 100 95 100 100

90 95 99 98

83 88 95 99 98

40 95

70 90

90 100

80 100 50 90 100 60 95 80

90 100 70 95 80

Page 4 of 4 UK NEQAS for H&I is provided from the Welsh Blood Service which is a division of Velindre NHS Trust © Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I